Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost - 15/01/19
, Francis Fagnani b, Gabrielle Cukierman c, Thibault de Chalus c, Jean-Michel Joubert c, Caroline Laurendeau b, Julie Gourmelen d, Maxime Breban e, f, gBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Severe SpA prevalence was estimated at 0.18%, corresponding to 87,979 cases in France in 2012. |
• | Severe hypertension, atrial fibrillation and depression appeared to be overrepresented in patients with severe SpA. |
• | Mean per capita healthcare expenditure was 3.6-fold higher in severe SpA patients than in controls. |
Abstract |
Objectives |
To estimate the number of patients with severe spondyloarthritis (SpA) in France, describe their comorbidities and document and value their healthcare resource consumption.
Methods |
Data were retrieved from an insurance claims database covering a 1/97 random sample of the French population. All patients benefiting from full insurance coverage (“ALD”) for severe SpA in 2012 (including cases with structural damage and/or frequent flares) were identified, together with a control group frequency-matched by age and gender. Severe comorbidities were documented through ALD categories. Healthcare resource consumption was documented and valued from the payer's perspective. Rates of comorbidities and costs were compared in SpA patients versus controls using non-parametric testing.
Results |
Overall, 827 patients with ALD status for severe SpA were identified (control group: n=2.481), corresponding to a prevalence rate of 0.18% [0.17–0.19] for SpA with ALD in the general population. Severe comorbidities more frequent in patients with SpA than in controls included inflammatory bowel disorders (odds ratio: 15.0 [6.2–36.2]), hypertension (2.5 [1.6–3.9]), atrial fibrillation (4.3 [1.9–9.6]) and major depressive disorder (2.1 [1.3–3.6]). Mean per capita annual direct healthcare expenditure was 3.6 [3.2–4.1]-fold higher in SpA patients (€6,122 [€5,838–€6,406]) than in controls (€1,682 [€1,566–€1,798]). Extrapolating to all patients in France, total healthcare cost attributable to severe SpA patients was €391 [€355–€426] million, with medication accounting for 53.8% of this cost.
Conclusions |
The burden of severe SpA in France is substantial, due to the high prevalence, high direct costs and associated comorbidities.
Le texte complet de cet article est disponible en PDF.Keywords : Spondyloarthritis, Échantillon généraliste des bénéficiaires, Disease burden, Direct costs
Plan
Vol 86 - N° 1
P. 69-75 - janvier 2019 Retour au numéro
Article précédent
- Decreased PD-1 expression on circulating CD4+T cell and PD-L1 expression on myeloid dendritic cell correlate with clinical manifestations in systemic juvenile idiopathic arthritis
- Li Cai, Chenxing Zhang, Jing Wu, Wei Zhou, Tongxin Chen
- IMSYC immunologic synovitis score: A new score for synovial membrane characterization in inflammatory and non-inflammatory arthritis
- Aurélie Najm, Benoît le Goff, Guillaume Venet, Thomas Garraud, Jérôme Amiaud, Noura Biha, Céline Charrier, Sophie Touchais, Vincent Crenn, Frédéric Blanchard, Veit Krenn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?